Information Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to inform you that the Company has preferred an appeal with the Hon'ble National Company Law Appellate Tribunal at New Delhi against the Judgement of NCLT, Chandigarh dated 12.03.2018. The above submission is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended 31St March, 2018
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent, viz., Mas Services Limited, which is a SEBI approved category-I, Registrar & Transfer Agent, registered with Securities and Exchange Board of India (SEBI Registration Number: INR000000049).... Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Thomas P. JoshuaDesignation :- Company Secretary and Compliance Officer Shareholding for the Period Ended March 31, 2018
Morepen Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order
The Hon'ble NCLT, Chandigarh vide order dated 12.03.2018 (received on 16.03.2018) has dismissed the Company's petition seeking approval of the Scheme of arrangement with the Fixed Deposit holders. Hon'ble NCLT has directed the Company to cancel those issued shares, under the scheme, which have not yet been transferred by original allottees (FD holders) and pay the amounts as per Company Law Board order dated 19.08.2003 within 3 months from the date... Analyst / Investor Meet - Outcome
Please find attached transcript of Investor and Analyst Conference Call organised on Tuesday, 23rd January, 2018 at 2.30 p.m. (IST) with regard to post declaration of Financial Results for the quarter and nine months ended 31st December 2017. This is for your information and records. Updates
Please find enclosed herewith the copy of the article on the Company published in Business India - January, 2018. Kindly acknowledge the receipt and take it on your record. Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that subsequent to the declaration of Financial Results for the quarter and nine-months ended 31st December 2017, the Company is organizing an 'Investor and Analyst Conference Call' on Tuesday, 23rd January, 2018 at 2.30 p.m. (IST). The details of the conference call are attached herewith. This is for your information and records. Investor Presentation
Please find enclosed the Investor Presentation - January, 2018, based on the financial performance of the Company for the quarter and nine-months ended 31st December, 2017. Kindly acknowledge the receipt and take it on your record. Diagnostic market helps Morepen Labs report 107% rise in Q3 net profit
The Q3 FY 2017-18 financial results were taken on record at a meeting of the company's board of directors here on Monday